RARE ALERT: GlaxoSmithKline said to ...

FTSE 100-listed GlaxoSmithKline, Switzerland-based Roche and Japan's Otsuka Pharmaceutical are all rumoured to be the large pharmaceutical companies involved in the strategic review being carried by Aurinia Pharmaceuticals, the US-listed rare disease drug developer.

People following the situation have heard speculation Goldman Sachs is advising Aurinia on the strategic review...